```json
{
"content": [
{
"type": "paragraph",
"content": "Genomic cancer testing involves the analysis of genetic mutations, gene expression profiles, and biomarkers to inform diagnosis, prognosis, and treatment decisions for oncology patients. This Genomic Cancer Testing market size reached $5.2 billion in 2025, reflecting its critical role in advancing precision medicine and improving therapeutic outcomes. With a projected growth outlook of a 13.8% CAGR from 2026–2033, the industry is positioned for sustained industry expansion driven by technological innovation, rising personalized medicine adoption, and increasing cancer incidence globally."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Targeted Sequencing", "Whole Genome Sequencing", "Liquid Biopsy"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 100], // Targeted Sequencing
[25, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48], // Whole Genome
[10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 35] // Liquid Biopsy
]
}
},
{
"type": "paragraph",
"content": "The market forecast highlights three pivotal forces shaping the Genomic Cancer Testing market: (1) Next-Generation Sequencing (NGS) advancements enabling multi-gene panel testing at lower costs, (2) regulatory approvals streamlining companion diagnostic pathways, and (3) rising patient awareness of early detection benefits. North America dominates the current market, while Asia-Pacific emerges as the fastest-growing region due to expanding healthcare infrastructure and government-funded oncology programs. Competitive intensity remains high, with mergers and AI-driven analytics accelerating industry consolidation."
}
]
}
```
